行情

GLPG

GLPG

Galapagos
NASDAQ

实时行情|Nasdaq Last Sale

69.76
-1.97
-2.75%
交易中 13:32 06/23 EDT
开盘
70.77
昨收
71.73
最高
71.02
最低
69.19
成交量
27.39万
成交额
--
52周最高
214.36
52周最低
69.19
市值
45.71亿
市盈率(TTM)
-14.1086
分时
5日
1月
3月
1年
5年
未来 6 个月需要关注的 14 只生物科技股
Biotechs are at the mercy of several make-or-break catalysts that invariably have a big impact on stocks.
Benzinga · 47分钟前
The Daily Biotech Pulse:Gemini 依据数据,安进 (Amgen) 的偏头痛药物在日本获得批准,肝脏大会正在进行中
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 22)
Benzinga · 5小时前
加拉帕戈斯首席科学官将于今年晚些时候离职
MT Newswires · 1天前
简报-Galapagos NV 称公司通过行使认购权增加股本
reuters.com · 06/07 20:05
BRIEF-Galapagos To Present Data On Rheumatoid Arthritis At The Upcoming European League Against Rheumatism (Eular) Congress
reuters.com · 05/27 22:11
焦点-大型制药公司和私募股权公司在欧洲东部寻求健康回报
reuters.com · 05/20 06:00
每日生物技术动向:难以延缓癌症治疗的监管备案,通过生物学的启程,沉默疗法的积极读数
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 18)
Benzinga · 05/19 11:30
加拉帕戈斯宣布参加FILOSOPHY研究的第一位患者,“以在现实世界中增进对Jyseleca(filgotinib)的有效性和安全性的了解”
Galapagos announces first patient enrolled in FILOSOPHY study to advance understanding of Jyseleca (filgotinib) effectiveness and safety in a real-world setting Study uses mobile device technology to support
Benzinga · 05/18 20:03
更多
财务预测
实际值(美元)
预测值(美元)
利润表更多
净利润(美元)
同比(%)
资产负债表更多
总资产(美元)
总负债(美元)
资产负债率(%)
现金流表更多
经营现金流(美元)
同比(%)
了解GLPG最新的财务预测,通过GLPG每股收益,每股净资产,每股现金流等数据分析Galapagos近期的经营情况,然后做出明智的投资选择。
分析师评级

10位分析师的综合评级

中性

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测
分析师预测GLPG价格均价为92.54,最高价位117.23,最低价为67.56。
EPS
机构持股
总机构数: 220
机构持股: 848.90万
持股比例: 12.96%
总股本: 6,552.25万
类型机构数股数
增持
48
194.69万
建仓
38
97.98万
减持
25
56.28万
平仓
19
26.00万
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
生物技术和医学研究
-0.75%
制药与医学研究
-0.53%
高管信息
Chairman - Management/Chief Executive Officer/Executive Director
Onno van de Stolpe
Non-Executive Chairman
Raj Parekh
Non-Executive Chairman
Rajesh Parekh
Chief Financial Officer/Chief Operating Officer/Executive Board
Bart Filius
Chief Scientific Officer/Executive Board
Piet Wigerinck
Vice President/IR Contact Officer
Elizabeth Goodwin
Executive Board
Walid Abi-Saab
Executive Board
Andre Hoekema
Non-Executive Independent Director
Katrine Bosley
Non-Executive Independent Director
Werner Cautreels
Non-Executive Director
Harrold van Barlingen
Non-Executive Independent Director
Mary Kerr
Non-Executive Independent Director
Christine Mummery
暂无数据
GLPG 简况
Galapagos NV is a Belgium-based clinical-stage biotechnology company. The Company is focused on the discovery and development of small molecule medicines with novel modes of action. Its pipeline comprises Phase 3, 2, 1, pre-clinical studies and discovery small-molecule and antibody programs in cystic fibrosis, inflammation, and other indications. The Company aims to develop a portfolio of clinical-stage therapies for the enhancement of existing treatment paradigms. In addition, the Company’s mission is to develop a number of medicines based on the discovery of novel targets. Galapagos NV also discovers which proteins that are involved in causing diseases such as, rheumatoid, arthritis, inflammatory bowel disease and fibrosis. Galapagos aims to develop small molecules that inhibit these targets, restore the balance and thereby positively influence the course of the disease.

微牛提供Galapagos NV(NASDAQ-GLPG)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的GLPG股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易GLPG股票基本功能。